In our article titled A Renal Indication for Semaglutide (Ozempic) (Med Lett Drugs Ther 2025; 67:38), the MACE endpoint defined in Table 2, footnote 3 was incorrectly stated as a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or all-cause mortality. All-cause mortality should not have been included in the composite endpoint.